Vyepti Side Effects

Generic name: eptinezumab

Medically reviewed by Philip Thornton, DipPharm. Last updated on Apr 29, 2022.

Note: This document contains side effect information about eptinezumab. Some of the dosage forms listed on this page may not apply to the brand name Vyepti.

For the Consumer

Applies to eptinezumab: intravenous solution

Side effects requiring immediate medical attention

Along with its needed effects, eptinezumab (the active ingredient contained in Vyepti) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking eptinezumab:

Less common

Chest tightness
fast heartbeat
feeling of warmth
fever
hives, itching, skin rash
hoarseness
irritation
joint pain, stiffness or swelling
large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, sex organs
redness of the skin
redness of the face, neck, arms and occasionally, upper chest
swelling of the eyelids, face, lips, hands, or feet
trouble breathing or swallowing

Incidence not known

Cough
dizziness
unusual tiredness or weakness

Side effects not requiring immediate medical attention

Some side effects of eptinezumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Headache
muscle aches
sore throat
stuffy or runny nose

Incidence not known

Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site

For Healthcare Professionals

Applies to eptinezumab: intravenous solution

General

The most commonly reported adverse reactions have been nasopharyngitis and hypersensitivity.^[Ref]

Hypersensitivity

Common (1% to 10%): Hypersensitivity

Frequency not reported: Anaphylactic reactions

Hypersensitivity reactions included terms, such as hypersensitivity, pruritus, and flushing/hot flush, occurring on the day of dosing. Hypersensitivity was reported in up to 3% and up to 4% of patients receiving doses of 100 mg or 300 mg, respectively